Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/10/2019
SIETES contiene 92824 citas

 
 
 1 a 20 de 57 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Raskind MA, Peskind ER, Chow B, Harris C, Davis-Karim A, Holmes HA, Hart KL, McFall M, Mellman TA, Reist C, Romesser J, Rosenheck R, Shih M-C, Stein MB, Swift R, Gleason T, Lu Y, Huang GD. Trial of prazosin for post-traumatic stress disorder in military veterans. N Engl J Med 2018;378:8 de febrero. [Ref.ID 102524]
2.Enlace a cita original Cita con resumen
Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]
3. Cita con resumen
Anónimo. Incontinences urinaires d'origine médicamenteuse. Prescrire 2015;35:271-4. [Ref.ID 99126]
4. Cita con resumen
6. Cita con resumen
Chang C, Gershwin ME. Drug-induced lupus erythematosus. Incidence, management and prevention. Drug Saf 2011;34:357-74. [Ref.ID 90404]
7. Cita con resumen
Anónimo. Digoxine: gare aux interactions médicamenteuses graves. Prescrire 2009;29:908-11. [Ref.ID 87340]
8.Enlace a cita original
Montero Corominas D, García del Pozo J, de Abajo FJ. Utilización de antihipertensivos en España, 1992-2006. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2009:1-14. [Ref.ID 86455]
9.
Malone M. Medications associated with weight gain. Ann Pharmacother 2005;39:2046-55. [Ref.ID 75965]
10.
Ouslander JG. Management of overactive bladder. N Engl J Med 2004;350:786-99. [Ref.ID 69168]
11. Cita con resumen
Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet 2003;361:1359-67. [Ref.ID 65789]
12. Cita con resumen
Anónimo. Managing lower urinary tract symptoms in men. Drug Ther Bull 2003;41:18-21. [Ref.ID 65442]
13. Cita con resumen
Kassabian VS. Sexual function in patients treated for benign prostatic hyperplasia. Lancet 2003;361:60-2. [Ref.ID 64738]
14. Cita con resumen
Plans Rubió P, Tresserras Gaju R, Navas Alcalá E, Pardell Alentá H. Estudio de coste-efectividad del tratamiento de la hipertensión arterial en Cataluña. Med Clin (Barc) 2002;118:211-6. [Ref.ID 60513]
15.
Barry MJ, Roehrborn C G. Benign prostatic hyperplasia. BMJ 2001;323:1042-6. [Ref.ID 59391]
16.
Khedun SM, Maharaj B, Moodley J. Effects of antihypertensive drugs on the unborn child: what is known, and how should this influence prescribing?. Paediatr Drugs 2000;2:419-36. [Ref.ID 54587]
17. Cita con resumen
Pritchard J. Drug-induced stroke. Adv Drug React Bull 2000;202:771-4. [Ref.ID 51339]
18.
Couture JA, Valiquette L. Urinary incontinence. Ann Pharmacother 2000;34:646-55. [Ref.ID 50711]
19. Cita con resumen
Sokol SI, Cheng A, Frishman WH, Kaza CS. Cardiovascular drug therapy in patients with hepatic diseases and patients with congestive heart failure. J Clin Pharmacol 2000;40:11-30. [Ref.ID 48842]
20.
Olyaei AJ, deMattos AM, Bennett WM. A practical guide to the management of hypertension in renal transplant recipients. Drugs 1999;58:1011-27. [Ref.ID 48396]
Seleccionar todas
 
 1 a 20 de 57 siguiente >>